Marker Therapeutics, Inc.
MRKR
$1.27
$0.086.72%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.70M | 5.39M | 5.70M | 6.59M | 5.40M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.70M | 5.39M | 5.70M | 6.59M | 5.40M |
| Cost of Revenue | 12.40M | 12.40M | 10.56M | 10.00M | 7.53M |
| Gross Profit | -7.70M | -7.01M | -4.86M | -3.41M | -2.14M |
| SG&A Expenses | 4.37M | 4.20M | 4.39M | 4.24M | 4.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.11M | 20.07M | 18.42M | 17.71M | 15.59M |
| Operating Income | -14.41M | -14.68M | -12.72M | -11.12M | -10.19M |
| Income Before Tax | -14.25M | -14.56M | -12.73M | -10.68M | -9.63M |
| Income Tax Expenses | 50.00K | 50.00K | 50.00K | 50.00K | 3.70K |
| Earnings from Continuing Operations | -14.30 | -14.61 | -12.78 | -10.73 | -9.63 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -62.90K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.30M | -14.61M | -12.78M | -10.73M | -9.70M |
| EBIT | -14.41M | -14.68M | -12.72M | -11.12M | -10.19M |
| EBITDA | -- | -- | -- | -- | -2.24M |
| EPS Basic | -1.23 | -1.36 | -1.32 | -1.19 | -1.09 |
| Normalized Basic EPS | -0.74 | -0.82 | -0.80 | -0.74 | -0.68 |
| EPS Diluted | -1.23 | -1.37 | -1.33 | -1.20 | -1.09 |
| Normalized Diluted EPS | -0.74 | -0.82 | -0.80 | -0.74 | -0.68 |
| Average Basic Shares Outstanding | 51.00M | 43.16M | 38.12M | 35.92M | 35.63M |
| Average Diluted Shares Outstanding | 51.00M | 43.16M | 38.12M | 35.92M | 35.63M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |